Background： Long-term use of benzalkonium chloride （BAC）-preserved drugs is often associated with ocular surface toxicity. Ocular surface symptoms had a substantial impact on the glaucoma patients＇ quality of life...Background： Long-term use of benzalkonium chloride （BAC）-preserved drugs is often associated with ocular surface toxicity. Ocular surface symptoms had a substantial impact on the glaucoma patients＇ quality of life and compliance. This study aimed to investigate the effects of sodium hyaluronate （SH） on ocular surface toxicity induced by BAC-preserved anti-glaucoma medications treatment. Methods： Filly-eight patients （101 eyes）, who received topical BAC-preserved anti-glaucoma medications treatment and met the severe dry eye criteria, were included in the analysis. All patients were maintained the original topical anti-glaucoma treatment. In the SH-treated group （56 eyes）, unpreserved 0.3% SH eye drops were administered with 3 times daily for 90 days. In the control group （55 eyes）, phosphate-butTered saline were administered with 3 times daily for 90 days. Ocular Surface Disease Index （OSDI） questionnaire, break-up time （BUT） test, corneal fluorescein staining, corneal and conjunctival rose Bengal staining, Schirmer test, and conjunctiva impression cytology were pertbrmed sequentially on days 0 and 91. Results： Compared with the control group, SH-treated group showed decrease in OSDI scores （Kruskal-Wallis test： H = 38.668, P 〈 0.001 ）, fluorescein and rose Bengal scores （Wilcoxon signed-ranks test： z = -3.843, P 〈 0.001, and z = 3.508, P 〈 0.001, respectively）, increase in tear fihn BUT （t-test： t - -10.994, P 〈 0.001 ） and aqueous tear production （t-test： t = -10.328, P 〈 0.001 ） on day 91. The goblet cell density was increased （t-test： t = -9.981, P 〈 0.001）, and the morphology of the conjunctival epithelium were also improved after SH treatment. Conclusions： SH significantly improved both symptoms and signs of ocular surface damage in patients with BAC-preserved anti-glaucoma medications treatment. SH could be proposed as a new attempt to reduce ocular surface toxicity, and alleviate symptoms of ocular surface damage in BAC-preserved anti-glaucoma medications treatment.展开更多
文摘Background： Long-term use of benzalkonium chloride （BAC）-preserved drugs is often associated with ocular surface toxicity. Ocular surface symptoms had a substantial impact on the glaucoma patients＇ quality of life and compliance. This study aimed to investigate the effects of sodium hyaluronate （SH） on ocular surface toxicity induced by BAC-preserved anti-glaucoma medications treatment. Methods： Filly-eight patients （101 eyes）, who received topical BAC-preserved anti-glaucoma medications treatment and met the severe dry eye criteria, were included in the analysis. All patients were maintained the original topical anti-glaucoma treatment. In the SH-treated group （56 eyes）, unpreserved 0.3% SH eye drops were administered with 3 times daily for 90 days. In the control group （55 eyes）, phosphate-butTered saline were administered with 3 times daily for 90 days. Ocular Surface Disease Index （OSDI） questionnaire, break-up time （BUT） test, corneal fluorescein staining, corneal and conjunctival rose Bengal staining, Schirmer test, and conjunctiva impression cytology were pertbrmed sequentially on days 0 and 91. Results： Compared with the control group, SH-treated group showed decrease in OSDI scores （Kruskal-Wallis test： H = 38.668, P 〈 0.001 ）, fluorescein and rose Bengal scores （Wilcoxon signed-ranks test： z = -3.843, P 〈 0.001, and z = 3.508, P 〈 0.001, respectively）, increase in tear fihn BUT （t-test： t - -10.994, P 〈 0.001 ） and aqueous tear production （t-test： t = -10.328, P 〈 0.001 ） on day 91. The goblet cell density was increased （t-test： t = -9.981, P 〈 0.001）, and the morphology of the conjunctival epithelium were also improved after SH treatment. Conclusions： SH significantly improved both symptoms and signs of ocular surface damage in patients with BAC-preserved anti-glaucoma medications treatment. SH could be proposed as a new attempt to reduce ocular surface toxicity, and alleviate symptoms of ocular surface damage in BAC-preserved anti-glaucoma medications treatment.
